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Abstract
Background
Nucleic acid amplification tests (NAATs) are increasingly being used as diagnostic tools for
soil-transmitted helminths (STHs; Ascaris lumbricoides, Trichuris trichiura, Necator ameri-
canus, Ancylostoma duodenale and A. ceylanicum), Strongyloides stercoralis and Schisto-
soma in human stool. Currently, there is a large diversity of NAATs being applied, but an
external quality assessment scheme (EQAS) for these diagnostics is lacking. An EQAS
involves a blinded process where test results reported by a laboratory are compared to
those reported by reference or expert laboratories, allowing for an objective assessment of
the diagnostic performance of a laboratory. In the current study, we piloted an international
EQAS for these helminths (i) to investigate the feasibility of designing and delivering an
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the different NAAT protocols used.
Methods and principal findings
A panel of twelve stool samples and eight DNA samples was validated by six expert labora-
tories for the presence of six helminths (Ascaris, Trichuris, N. americanus, Ancylostoma,
Strongyloides and Schistosoma). Subsequently this panel was sent to 15 globally dispersed
laboratories. We found a high degree of diversity among the different DNA extraction and
NAAT protocols. Although most laboratories performed well, we could clearly identify the
laboratories that were poorly performing.
Conclusions/Significance
We showed the technical feasibility of an international EQAS for the NAAT of STHs, Stron-
gyloides and Schistosoma. In addition, we documented that there are clear benefits for par-
ticipating laboratories, as they can confirm and/or improve the diagnostic performance of
their NAATs. Further research should aim to identify factors that explain poor performance
of NAATs.
Author summary
Tests that detect parasite DNA in human stool are increasingly being used for the diagno-
sis of infections with intestinal worms, including schistosomiasis. To ensure the quality in
diagnostic testing of these parasitic worms, it is important that laboratories evaluate the
diagnostic performance of their DNA-based tests. This can best be achieved by participat-
ing in an external quality assessment scheme (EQAS). An EQAS involves a blinded pro-
cess where test results reported by a laboratory are compared to those reported by
reference or expert laboratories, allowing for an objective assessment of the diagnostic
performance of a laboratory. Currently, such an EQAS for parasitic worms is lacking. We
therefore piloted an international EQAS for the diagnosis of parasitic worms involving 15
laboratories in Africa, Asia, Australia, Europe, and North America. Although most labora-
tories performed well, we could clearly identify those laboratories that may need to
improve their test protocol. We found that laboratories were using many different test
protocols, and further research should aim to verify whether this has an impact on the per-
formance of the diagnostic outcomes.
Introduction
Soil-transmitted helminths (STHs, i.e. Ascaris lumbricoides, Trichuris trichiura and the hook-
worms Ancylostoma duodenale, Ancylostoma ceylanicum and Necator americanus), Strongy-
loides stercoralis and Schistosoma (S. mansoni, S. haematobium and S. japonicum) are parasitic
worms that still impose a burden on global health. The STHs affect one-fifth of the world’s
population and cause 1.9 million disability adjusted life-years (DALYs) [1]. Schistosomiasis
affects 230 million people [2] and has been estimated to cause 1.4 million DALYs [3]. S. stercor-
alis has an estimated global prevalence of 370 million [4], but the global burden is still to be
determined. Although these infections mainly affect the poorest populations in low- and
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middle-income countries, hookworms and S. stercoralis are also found in low-income regions
of the United States [5], marginalized communities in Europe [6] and in Indigenous popula-
tions in Australia [7,8]. In addition, strongyloidiasis and schistosomiasis are important travel-
related diseases, causing substantial morbidity, both in travelers and migrants moving from
endemic to non-endemic countries [9,10].
Diagnosis of these parasites is still largely based on the detection of worm eggs or larvae in
stool or, in the case of S. haematobium, eggs in urine samples. However, nucleic acid amplifica-
tion tests (NAATs) are increasingly being used as diagnostic tools for soil-transmitted helmin-
thiasis, strongyloidiasis and schistosomiasis [11]. For example, NAATs are already considered
the standard diagnostics in some clinical laboratories in high-income countries [12,13]. In the
public health field, NAATs are being explored as diagnostic tools to assess the distribution of
prevalence and infection intensity at the population level in endemic areas [14]. These parasi-
tological indicators are used to guide both the implementation and evaluation of large-scale
deworming programs that aim to control the morbidity attributable to soil-transmitted hel-
minthiasis and schistosomiasis [15].
Currently, a large diversity of available NAATs are being applied, but there is no external
quality assessment scheme (EQAS) to support the use of these diagnostics [16,17]. However,
such EQAS are essential to attain the highest achievable diagnostic quality and to improve
health outcomes in terms of care and treatment at the individual level, as well as monitoring of
disease burden and response to control at the population level. An EQAS involves a blinded
process in which test results reported by a laboratory are compared to those reported by refer-
ence or expert laboratories testing the same panel of samples, allowing for an objective assess-
ment of the diagnostic performance of a laboratory [18]. EQAS have already proven to be
essential to highlight weaknesses in NAATs used for the diagnosis of other parasitic and tropi-
cal diseases such as diarrhea-causing protozoa [19], malaria [20], yellow fever [21] and Zika
[22].
In the current study, we piloted an EQAS for the DNA-based detection of Schistosoma and
STHs, including Strongyloides, the so-called Helminth External Molecular Quality Assessment
Scheme (HEMQAS). The objectives of this HEMQAS pilot were (i) to investigate the feasibility
of designing and delivering a technically and logistically challenging EQAS for the detection of
Schistosoma and STHs, including Strongyloides in both preserved stool and DNA samples, (ii)
to evaluate and compare the diagnostic performance of laboratories, and (iii) to gain insights
in the diversity of the different NAAT protocols used.
Methodology
Ethics
This study was part of work package 1 of the Starworms study (www.starworms.org). The Star-
worms study was registered (Belgian registration number B670201627755) and approved by
the Ethics Committee of the Faculty of Medicine and Health Sciences of Ghent University and
the Ghent University Hospital, Belgium (reference number 2016/0266). Local approval was
obtained at the Institutional Review Board of Jimma University, Ethiopia (reference number
RPGC/547/2016). The school director, teachers, parents or legal guardians, and children were
informed about the objectives and procedures of the study. Written informed consent was
obtained from the parents or legal guardians of all participating children. Participation was
voluntary. In addition to samples obtained from these children, two stool samples were col-
lected from a person living in a non-endemic region, after obtaining a written consent.
S. stercoralis infective third-stage larvae used in this study were from a canine strain main-
tained in purpose-bred laboratory dogs housed a vivarium at the University of Pennsylvania
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(Philadelphia, USA). This vivarium is accredited by the International Association for
Assessment and Accreditation of Laboratory Animal Care. Dogs were infected with
S. stercoralis and maintained thereafter in accordance with protocols 804798 and 804893
approved by the University of Pennsylvania Institutional Animal Care and Use Committee.
All protocols, as well as routine husbandry care of the animals, were carried out in strict
accordance with the Guide for the Care and Use of Laboratory Animals of the US National
Institutes of Health.
Nomenclature
In the context of collecting samples for the HEMQAS study, we use the species names of the
helminths where appropriate. In the context of the HEMQAS panel, given that not all experts
laboratories used species specific assays (see further), we refer to the respective HEMQAS sam-
ples as being validated for Ascaris, Ancylostoma, Schistosoma, Strongyloides and Trichuris
(even though microscopic screening and/or epidemiology allowed speciation). We used the
term N. americanus throughout the manuscript, given that all expert laboratories used species
specific assays for N. americanus.
Designing and delivering HEMQAS
We designed and delivered HEMQAS through three consecutive steps (Fig 1). In the prepara-
tory phase, we identified the expert and participating laboratories, collected the samples and
prepared the panel. Expert laboratories were identified and defined based on their scientific
track record on molecular diagnostics for STHs and Schistosoma and authority in this field. In
addition, we developed a questionnaire to gain insights into the diversity in NAAT protocols.
Next, the HEMQAS panel was distributed to the expert laboratories, which validated the pro-
cedures of homogenizing and aliquoting samples, and the targets in the panel. In a final step,
the HEMQAS panel was distributed to the participating laboratories, which reported their
findings and received feedback on their diagnostic performance. In the following paragraphs
we will discuss each of the three steps in more detail.
Preparatory phase
(i) Coordination and identification of laboratories. The study was coordinated by the
Laboratory of Parasitology of Ghent University and the Department of Medical Microbiology
and Infectious diseases (Erasmus University Medical Center), which is the coordinating center
for parasitological EQAS of the Dutch Foundation for Quality Assessment in Medical Labora-
tories (SKML; www.skml.nl). The SKML has long-term experience in setting up EQAS and
Fig 1. Overview of the different steps, the expert and participating laboratories of the HEMQAS pilot study.
https://doi.org/10.1371/journal.pntd.0008231.g001
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has already established an international EQAS for the DNA-based diagnosis of intestinal pro-
tozoa [19].
We aimed to include expert laboratories for the validation of the HEMQAS panel in such
way that each target (Ascaris, Trichuris, Ancylostoma, N. americanus, Strongyloides and Schisto-
soma) was validated by a minimum of five expert laboratories geographically dispersed around
the world. Expert laboratories were considered if their NAAT protocols had been published or
when their expertise on NAATs was internationally acknowledged. Based on these criteria,
two clinical and four research laboratories across Australia (n = 1), Europe (n = 3) and the
USA (n = 2) were identified as expert laboratories (Table 1). Each of these laboratories com-
mitted to examine the HEMQAS panel in a blinded way and to discuss the overall obtained
results applying a priori defined criteria explained below.
For the actual HEMQAS pilot study, nine laboratories were identified within the network
of the HEMQAS coordinators (Table 1). Here, we only considered laboratories for participa-
tion if they had an operational NAAT for at least two of the six targets. We also aimed to
include participants from both endemic and non-endemic countries. Furthermore, all six
expert laboratories that were involved in the validation of the HEMQAS samples were also
Table 1. The expert and participating laboratories of the HEMQAS pilot study. The order of the list does not correspond with the order of the laboratories in Table 5.
Country Institution/Organization Laboratory/Department Laboratory type
Expert laboratories
Australia QIMR Berghofer Medical Research Institute The Clinical Tropical Medicine Laboratory Research
laboratory
The
Netherlands
Erasmus Medical Center Department of Medical Microbiology and Infectious
Diseases
Clinical
laboratory
The
Netherlands
Elisabeth TweeSteden Hospital Laboratory of Medical Microbiology and Immunology Clinical
laboratory
The
Netherlands
Leiden University Medical Center Department of Parasitology Research
laboratory
USA Baylor College of Medicine Laboratory of Clinical Parasitology and Diagnostics Research
laboratory
USA Smith College and the University of Massachusetts Department of Biological Sciences and Biochemistry;
Program in Molecular and Cellular Biology
Research
laboratory
Participating laboratories
Australia University Melbourne Melbourne Veterinary School Research
laboratory
Belgium Institute of Tropical Medicine Central Laboratory for Clinical Biology Clinical
laboratory
India Christian Medical College, Vellore The Wellcome Trust Research Laboratory Research
laboratory
Kenya Kenya Medical Research Institute Eastern and Southern Africa Centre of International
Parasite Control
Research
laboratory
Malaysia Universiti Sains Malaysia Institute for Research in Molecular Medicine Research
laboratory
Uganda Medical Research Council/Uganda Virus Research Unit & London School
of Hygiene and Tropical Medicine Uganda Research Unit
Immunity and Vaccines Programme Research
laboratory
USA Centers for Disease Control and Prevention Parasitic Diseases Branch Research
laboratory
USA PATH Diagnostics Program Research
laboratory
USA Washington University in St. Louis Infectious Diseases Division Research
laboratory
https://doi.org/10.1371/journal.pntd.0008231.t001
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included as participating laboratories, resulting in a total of 15 laboratories. Eleven laboratories
were research laboratories and four of the 15 laboratories were clinical laboratories. Two labo-
ratories were from Africa, two from Asia, two laboratories from Australia, four from Europe,
and five from the USA. Participating in the study was free of charge.
(ii) Collection of specimens and preparation of the panel. The HEMQAS panel
included both a stool panel and a DNA panel. For the stool panel, a total of 12 stool samples
were collected. Ten of these clinical stool samples were collected in Jimma (Ethiopia) as part of
the Starworms study [23]. Stool samples from school-aged children in which one of the STH
species or S. mansoni had been detected using the Kato-Katz technique [23] were preserved in
ethanol by filling half of a 50 ml Falcon tube with stool and suspending this in 25 ml of 96%
ethanol. These ten stool samples were selected, as much as possible, to include mixed infec-
tions in order to maximize the total number of targets while minimizing the number of sam-
ples. The samples were kept refrigerated until shipment at ambient temperature to the
Laboratory of Parasitology (Ghent University, Belgium). Two stool samples were collected
from one person in Belgium. One of these stool samples was spiked with S. stercoralis third-
stage larvae at a concentration of 200 larvae per gram (Table 2) before being further diluted
circa 40 times, the other stool sample was used as a negative control. All stool samples were
homogenized, further diluted as needed, and aliquoted according to the in-house method of
SKML applied for its protozoa EQAS panel [19].
For the HEMQAS DNA panel, worm materials were obtained from different partners
(Table 2). DNA from adult A. lumbricoides worms (only the heads were used), N. americanus
third-stage larvae, S. stercoralis infective third-stage larvae and S. mansoni adult worms was
extracted by one expert laboratory (Elisabeth-TweeSteden Hospital, Tilburg, The Nether-
lands). For this, the QIAamp DNA Mini Kit (Qiagen) was used according to the manufactur-
er’s guidelines. The quantity of the DNA was measured using the Qubit fluorometer. From
each DNA extract, a tenfold dilution was made and included in the DNA panel, resulting in a
total of eight DNA extracts.
(iii) Development of QBase and questionnaire. In order to gain insights into the differ-
ent NAAT protocols used by the participants, we developed a questionnaire that was incorpo-
rated into QBase. QBase is an online results submission tool developed and used by SKML for
other EQAS. It was adapted to fit the specific needs of this pilot study. A summary manual and
an extended manual were developed to introduce all participants to this submission tool (S1
File).
Validation of the HEMQAS panel
Following the distribution of the panel to the expert laboratories, the panel was validated. The
validation of the panel was two-fold and was based on the procedures previously described by
Schuurs and coworkers [19]. First, we validated the procedures for homogenizing and aliquot-
ing stool samples. Second, we validated the targets in the panel. In the following paragraphs we
will discuss each of the steps in more detail.
Table 2. Origin and type of worm material used for the HEMQAS panel.
Species Origin Host Type of material
Ascaris lumbricoides Jimma, Ethiopia Human Adult worm
Necator americanus Leiden, The Netherlands Human Third-stage larvae
Schistosoma mansoni Rotterdam, The Netherlands Hamster Adult worms
Strongyloides stercoralis Philadelphia, United States Dog Third-stage larvae
https://doi.org/10.1371/journal.pntd.0008231.t002
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(i) Distribution of the panel. The HEMQAS panel for validation consisted of twenty
samples (twelve ethanol-preserved stool samples and eight DNA samples) and was sent out to
the six expert laboratories who received the samples blinded. For validation, the panels were
organized in such a way that each expert laboratory received three or four samples as quintu-
plicates (i.e., five aliquots) and the remaining 16 to 17 samples as single aliquots, and that the
different quintuplicates were equally dispersed over the expert laboratories. Given that there
were six laboratories and a panel of twenty samples, some expert laboratories received three
samples as quintuplicates and 17 samples as single aliquots, and the other expert laboratories
received four samples as quintuplicates and 16 samples as single aliquots. Expert laboratories
were asked to remove the ethanol from the ethanol-preserved stool samples according to a
standard SKML protocol that was sent along with the samples (see S2 File). Further, expert
laboratories were asked to process and analyze all samples according to their in-house DNA
extraction and NAAT protocol.
(ii) Validation of stool homogenization and aliquoting methods. Eggs of STHs and
Schistosoma and larvae of S. stercoralis can be unequally dispersed in a stool sample. In order
to validate the homogenization and aliquoting procedures, quintuplicates of each sample were
analyzed by a single laboratory. We concluded that homogenization and aliquoting procedures
were appropriate when the standard deviation of the Cq-values of the targets with the lowest
Cq-values (i.e., the highest DNA concentration) across the quintuplicates did not exceed two.
We did not consider this criterion for targets for which the Cq-values were high (i.e., the lowest
DNA concentration), as a large variation in Cq-values is already expected (the variation in Cq-
values between the aliquots of the same samples increases as the DNA concentration drops
[24]).
(iii) Validation of the targets. At least five expert laboratories assessed all samples for all
targets, except for Schistosoma, which was assessed by four expert laboratories. All laboratories
were blinded to the microscopy data and the outcome of the other laboratories. Expert labora-
tories were asked to report their results to SKML within one month using a standard Excel file.
Reports were compiled by SKML and predefined criteria were applied to validate samples as
positive, negative or educational for a specific target (i.e., Ascaris, Trichuris, N. americanus,
Ancylostoma, Strongyloides and Schistosoma). A sample was validated as positive for a particu-
lar target when the following three criteria were fulfilled: (i) all quintuplicates analyzed by one
of the expert laboratories was positive for that target, (ii) the standard deviation of the Cq-val-
ues of the quintuplicates was less than two cycles, and (iii) all other expert laboratories con-
firmed the presence of that particular target. These criteria guarantee that DNA of the target
can be detected by state-of-the-art NAAT variants in all aliquots of the sample, and therefore,
a positive result by the participating laboratories can be demanded. A sample was classified as
negative for particular target when the two following criteria were fulfilled: (i) all quintupli-
cates analyzed by the expert laboratory were negative for that particular target and (ii) all other
expert laboratories confirmed the absence of that particular target. Samples that were not
validated as positive or negative for a specific target were considered as educational for this
particular target, meaning that the samples contained such a low parasite load that it was not
consistently detected by all the expert laboratories. Therefore, a positive result cannot be
demanded from each participating laboratory. These criteria are commonly applied by variety
of EQAS organizations, including but not limited to SKML. The results of this validation were
compiled, shared between expert laboratories (see S3 File) and discussed during a teleconfer-
ence call. Based on the results, it was decided to keep all 12 stool and 8 DNA samples in the
final HEMQAS panel. The composition of the HEMQAS stool and DNA panel is summarized
in Table 3. The 12 stool and 8 DNA samples included targets for five helminth targets (Ascaris,
Trichuris, N. americanus, Strongyloides and Schistosoma). Six of the 20 samples were validated
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as positive for Ascaris, two as positive for Trichuris, seven as positive for N. americanus, five as
positive for Schistosoma and one as positive for Strongyloides. Ten of the 20 samples were vali-
dated negative for Ascaris, twelve for Trichuris, sixteen for Strongyloides and fifteen for Schisto-
soma. The panel did not include Ancylostoma, and all samples were validated as negative for
this genus. The educational samples included four for Ascaris, six for Trichiura, two for N.
americanus and three for Strongyloides. For Schistosoma, there were no educational samples.
HEMQAS pilot study
(i) Distribution of the panel. The HEMQAS panels were sent to all participating labora-
tories at ambient temperature using an express courier. For each laboratory, the stool and
DNA panel samples were placed in protective sealed envelopes. Per stool and DNA sample, we
only sent one aliquot of 250 μl and 50 μl, respectively. No quintuplicates were sent in the pilot
study. Each package also contained instructions on how to remove the ethanol from stool,
prior to commencing DNA extraction procedures (see S2 File). No information on the out-
come of the validation was shared to the participating laboratories.
(ii) Reporting of the test results and completion of the questionnaire. All participating
laboratories were asked to process the panel according to their in-house DNA extraction and
NAAT protocols, and to report the results using the QBase submission tool. They were also
questioned about the main characteristics of both their DNA extraction procedures and
NAAT protocols by means of a questionnaire. Participants were allowed two months to com-
plete the analysis, submit their results and complete the questionnaire. This is longer than
what is normally giving during an EQAS by SKML, but the extra time was given to anticipate
logistical issues such as packages delayed at customs, and the need of laboratories to become
acquainted with the online QBase submission software.
Table 3. Composition of the HEMQAS stool (ST) and the DNA panel. Red cells represent samples that are classified as negative for that particular target; green cells
represent samples that are classified as positive for the target; orange cells represent samples that are classified as educational for the target.
Sample ID Ascaris Trichuris Necator
americanus
Ancylostoma Strongyloides Schistosoma
ST1
ST2
ST3
ST4
ST5
ST6
ST7
ST8
ST9
ST10
ST11
ST12
DNA1
DNA2
DNA3
DNA4
DNA5
DNA6
DNA7
DNA8
https://doi.org/10.1371/journal.pntd.0008231.t003
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(iii) Feedback on the diagnostic performance. After receiving the results from all partici-
pants, results were compiled and reported back to all participants by SKML. In these reports,
all participants received a complete anonymized list of all submitted results with only their
own laboratory recognizable. An example of such a report is provided in S4 File. For the cur-
rent study, the raw data were analyzed as described below.
Statistical analysis
We analyzed the diagnostic performance of the different NAATs across laboratories and tar-
gets by assessing the number of false positive (FP) and false negative (FN) test results. Educa-
tional samples were not considered in these analyses because interpretation of these results
requires more observations. We assessed the variation in DNA extraction and NAAT proto-
cols across the different participants. We did not explore associations between DNA extraction
or NAAT protocols and diagnostic performance. This is because the pilot study was not
designed nor powered to identify possible factors that may explain the variation in diagnostic
performance across laboratories. To gain insights into the variation in quantitative test results,
we assessed the variation in the reported Cq-values across the different targets and individual
samples. The stability of the DNA and stool panel was analyzed by comparing the Cq-values
obtained by the expert laboratories during the panel validation with those reported approxi-
mately six months later in the HEMQAS pilot study.
Results
Description of the DNA extraction and NAAT protocols
All participating laboratories completed the online questionnaire. A summary of the different
DNA extraction and NAAT protocols used by the 15 laboratories is provided in Table 4. All
laboratories used a commercial DNA extraction kit. Twelve laboratories applied a procedure
in which the helminth eggs were mechanically broken by bead beating, five included a freeze-
thaw cycle in the DNA extraction protocol, and two included a protease treatment, all in order
to increase DNA yield from the helminth eggs. There was a great deal of variation in the type
of beads (n = 11), bead beaters (n = 10) and DNA extraction kits (n = 10) used. Both the vol-
ume of stool suspensions used for DNA extraction and the elution volume differed substan-
tially between laboratories, ranging from 50 to 500 μl and from 50 to 200 μl, respectively. All
laboratories used quantitative PCR (qPCR) as NAAT, but in different formats. Six laboratories
used a multiplex qPCR and nine laboratories used different singleplex qPCRs. All qPCR assays
used hydrolysis probes to detect amplicons. There was a large diversity in master mixes used,
with almost every laboratory using a different master mix. Five of the fifteen laboratories ana-
lyzed the panels for the presence of all targets. Five laboratories had NAATs for all targets
except Schistosoma, two laboratories had all targets except Schistosoma and Strongyloides, two
laboratories only had NAAT available for Strongyloides and Schistosoma, and one laboratory
had qPCR protocols for Schistosoma, Strongyloides and N. americanus. The DNA template vol-
ume used in the NAATs ranged from 1 μl to 10 μl and the corresponding stool suspension
used per NAAT reaction ranged from 1.5 μl to 36.4 μl.
Stability of the targets over time
The mean difference of the Cq-values (± standard deviation) for all stool samples reported as
positive by the expert laboratories during the validation of the panel and those reported
approximately six months later during the actual HEMQAS pilot study by the same laborato-
ries was 1.8 ± 0.4 for Ascaris, -1.6 ± 1.7 for N. americanus, 0.8 ± 0.9 for Schistosoma and
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0.4 ± 0.6 for Trichuris. However, one stool sample that was validated as positive for Trichuris
by the five expert laboratories was found negative by three of these laboratories during the
pilot study. For the DNA samples, the mean difference (± standard deviation) was 0.6 ± 0.1 for
Ascaris, 0.5 ± 0.0 for N. americanus, 0.1 ± 0.1 for Schistosoma and 0.0 ± 0.6 for Strongyloides.
Given the minor variation over time of all targets, except for one Trichuris-positive stool sam-
ple, we concluded that the targets in both the stool and DNA panel were stable over time.
Diagnostic performance
The diagnostic performance assessed by the number of false positives (FPs) and false negatives
(FNs) across targets and/or laboratories is shown in Table 5. Of the total of 975 negative tar-
gets that were analyzed by the different laboratories, thirteen were FP test results. All of the FP
test results were reported by only two of the laboratories (laboratory B and N). Eight of these
were FP Strongyloides results reported by laboratory B and three were FP Schistosoma results
reported by laboratory N. Laboratory N also reported a FP N. americanus result. Across the
240 positive targets, there were a total of 30 FN test results. Of these, 23 FN test results were
Table 4. Overview of the different DNA extraction and NAAT protocols used in the HEMQAS pilot study. The
number between brackets corresponds to the number of laboratories. ITS-1, intergenic transcribed spacer-1; ITS-2,
intergenic transcribed spacer-2; 18S rRNA, 18S ribosomal ribonucleic acid; 28S rRNA, 28S ribosomal ribonucleic acid.
DNA extraction
Bead beating: Yes (12), No (3)
Type of beads: MagNA Lyser Green Beads (Roche) (1); Garnet beads 0.7 mm (SanBio) (1); Zirconia/silica beads 0.5
mm (Daintree Scientific) (1); Silica beads (1); Included in FastDNA SPIN kit for Soil (MP Biomedicals) (4); Mixture
of ceramic and silica particles (1); Included in ISOLATE II Faecal DNA extraction kit (Bioline) (1); Zirconium beads
1.5 mm (Benchmark Scientific) (1); Included in Precellys Lysing Kit (Bertin technologies) (1)
Bead beater: TissueLyser LT (Qiagen) (1); FastPrep (MP Biomedicals) (6); Mini-Beadbeater (Biospec Products) (1);
Beadbug (Benchmark Scientific) (1); Precellys 24 Tissue Homogenizer (Bertin technologies) (1); Vortex (2)
Proteinase K pretreatment: Yes (4), No (11)
Freeze-thaw cycle: Yes (5), No (10)
DNA extraction kit: MagnaPure (Roche) (1); Isolate II Faecal DNA Kit (Bioline) (1); Maxwell (Promega) (1);
Maxwell RSC PureFood GMO and Authentication kit (Promega) (1); FastDNA SPIN Kit for Soil (MP-Biomedicals)
(5); QIAamp DNA Mini Kit (Qiagen) (1); DNeasy Blood and Tissue Kit (Qiagen) (2); QIAamp Stool Kit (Qiagen)
(1); DNeasy PowerSoil Kit (formerly Powersoil kit sold by MO BIO) (3); QIA Symphony (Qiagen) (1)
NAAT
NAAT technology: qPCR (15)
qPCR format: Singleplex (9), Multiplex (6)
Detection: Hydrolysis probes (15)
Master mix: Qiagen (1); Quantitect (Qiagen) (2); HotStarTaq MasterMix (Qiagen) (2); Applied Biosystems (4);
VWR (1); Roche (1); Promega (1); Platinum qPCR Supermix-UDG with ROX (Thermofisher) (1); TaqPath ProAmp
Master (Thermofisher) (1); Technologies Brilliant II QPCR Master Mix (Agilent) (1)
Stool volume used for DNA extraction (mean, range): 223 μl, 50–500 μl
Elution volume (mean, range): 109 μl, 50–200 μl
DNA used for NAAT (mean, range): 3.2 μl, 1–10 μl
Stool volume used per NAAT reaction (mean, range): 8.6 μl, 1.5–36.4 μl
Ascaris primer and probe target: ITS-1 (10), non-coding repetitive DNA sequence (2)
Trichuris primer and probe target: 18S rRNA (4), 28S rRNA (1), ITS-1 (1), non-coding repetitive DNA sequence
(6)
Necator primer and probe target: ITS-1 (1), ITS-2 (6), non-coding repetitive sequence (5)
Schistosoma primer and probe target: 28S rRNA (1), cytochrome c oxidase (1), non-coding repetitive DNA
sequence (1), ITS-2 (4)
Strongyloides primer and probe target: 18S rRNA (8), non-coding repetitive sequence (5)
https://doi.org/10.1371/journal.pntd.0008231.t004
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reported by three laboratories, including laboratory M (n = 16), laboratory F (n = 4) and labo-
ratory H (n = 3). The other seven FNs were reported by seven different laboratories. Three lab-
oratories reported no FP and no FN test results. The number of educational samples found
positive for each target and laboratory are shown in Table 5.
Quantification
All laboratories reported results in relative quantification units, i.e. using a unit that reports
the cycle at which the fluorescence from the qPCR reaction exceeds the background fluores-
cence. None of the laboratories reported in absolute quantification units. Fig 2 illustrates the
variation in Cq-values reported across the different laboratories for each target and each sam-
ple separately. Overall, there was a large variation in reported Cq values. For example, across
laboratories, the variation for each of the seven N. americanus positive samples exceeded ten
Cq-values. The number of FN and FP results per laboratory and target as a function of the
reported Cq values are shown in Fig 3. Overall, there was no clear link between FP or FN and
the Cq-values. Because of the limited number of positive targets for Trichuris and Strongy-
loides, plots are not shown for these helminth species.
Discussion
NAATs are increasingly used for the detection and quantification of Schistosoma and STHs,
including Strongyloides, but an EQAS, a key component for an overall quality management
Table 5. The performance of 15 laboratories for the detection of six helminths in stool and DNA. The numbers in the second row represent the total number of true
negatives (TN), true positives (TP) and educational samples (Ed) per target. The laboratories are shown in the left column. The body of the table shows the number of
false-positive (FP), false-negative (FN) and educational (Ed) test results per laboratory and per target. Blue cells indicate FP results, red cells indicate FN results, green cells
indicate the absence of FP and FN results, black cells indicate that a NAAT has not been performed by a laboratory. The numbers in the blue, red and white cells indicate
the number of FP, FN or Ed results, respectively. The ‘All targets’ column, represents per laboratory across all targets the ratio of the totals of FP, FN and educational posi-
tives (EP) over the total number of TN, TP and Ed.
Ascaris Trichuris N. americanus Ancylostoma Strongyloides Schistosoma All targets
TN TP Ed TN TP Ed TN TP Ed TN TP Ed TN TP Ed TN TP Ed
10 6 4 12 2 6 11 7 2 20 0 0 16 1 3 15 5 0
Lab FP FN EP FP FN EP FP FN EP FP FN EP FP FN EP FP FN EP FP/TN FN/TP EP/Ed
A 3 6 1 3 1 0/84 1/21 13/15
B 8 3 8/31 0/6 3/3
C 2 0/31 0/6 2/3
D 3 6 0 2 0/84 0/21 11/15
E 3 1 0 1 2 0/69 1/16 6/15
F 2 1 3 3 0 2 0/84 4/21 7/15
G 3 1 0 0 2 0/84 1/21 5/15
H 2 2 1 0 1 2 0/69 3/16 5/15
I 3 0 1 1 1/53 0/15 4/12
J 3 1 0 1 2 0/69 1/16 6/15
K 2 1 4 0 0/53 1/15 6/12
L 2 1 0 0 2 0/69 1/16 4/15
M 6 0 2 0 7 0 1 0 0/69 16/16 0/15
N 1 1 0 2 3 4/42 1/13 2/5
O 2 0 0 1 0/84 0/21 3/15
Total 0 8 28 0 9 19 1 11 5 1 0 8 1 25 3 1 13/975 30/240 77/185
https://doi.org/10.1371/journal.pntd.0008231.t005
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system, is lacking. To our knowledge, we piloted the first international EQAS for the DNA-
based detection of these parasitic worms. In the current study, a total of 15 clinical and
research laboratories, representing both non-endemic and endemic countries, participated in
this EQAS for NAATs targeting Schistosoma and STH, including Strongyloides.
The HEMQAS panel was stable over the course of the study
For both the DNA and the stool panels, there were only small differences in quantitative results
reported among the expert laboratories during the validation of the panel and the pilot study,
which was completed approximately 6 months later. These findings demonstrate that both
panels were stable over the course of the study, and that discrepancies were not due to degra-
dation of DNA during long-term storage. These results correspond with previous reports that
showed that eggs from STHs in stool could be well preserved in ethanol over a one-year period
for subsequent examination by NAATs [25]. However, for one stool sample, there were dis-
crepant results between the validation round and the pilot study. This sample was validated as
a Trichuris positive sample, i.e., found positive by all expert laboratories during the validation
of the panel, but found negative by three of the expert laboratories in the pilot study. Further-
more, this sample was also found negative by five of the other participating laboratories. Retro-
spectively, the amount of Trichuris DNA in this stool sample was rather low (median reported
Cq-value of 34.8), comparable to that of the educational Trichuris samples (range median
reported Cq-values 30.8 to 35.4) and probably close to the limit of detection (LOD) of most
Fig 2. The variation in the reported Cq-values across the different targets and samples. The Cq-values reported by
the different participants for the different targets is shown on the Y-axis. The boxes represent the interquartile range;
the lines in the boxes represent the median values; the upper and lower whiskers represent the 95th and the 5th
percentile, respectively; and the dots represent outliers. The X-axis represents the different samples of the HEMQAS
panel (see Table 3).
https://doi.org/10.1371/journal.pntd.0008231.g002
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NAATs. In general, the probability of reporting a FN increases when the target DNA concen-
tration approaches the LOD, which probably explains these FN results, although the LODs of
the different NAATs are unknown. In cases where fewer than 50% of the participating labora-
tories report the expected positive result, it is common practice in EQAS organized by SKML
to change the status of that target from positive into educational. However, this was not done
during current pilot study. Knowledge of the absolute target concentrations of each sample
and the LODs of each NAAT would allow for better interpretation of such cases (see also
below).
Participation in HEMQAS enables identification of flaws in diagnostic
performance
Overall, the diagnostic performance of most laboratories was good. However, a substantial
number of FPs and FNs were reported. The majority of reported FPs in our study involved
Strongyloides reported by a single laboratory. Remarkably, all FP Strongyloides results reported
by this single laboratory were Ascaris positive stool and DNA samples. Hence, one of the possi-
ble explanations is that there was a cross-reaction between Strongyloides and Ascaris in the
qPCR protocols of this laboratory, e.g. due to unspecific primers and/or fluorescence cross-
over between channels. Another possibility is that Strongyloides negative samples were con-
taminated during laboratory manipulations and/or non-specific curves were considered as
specific DNA amplification, e.g. because of fluorescent crosstalk from other channels. The fact
that Strongyloides FP test results were reported both in the stool and the DNA panel empha-
sizes the need for including both stool and DNA samples in an EQAS for helminths. Indeed,
without including DNA samples, the laboratory reporting these FP results could have counter-
argued that their FP test results in the stool panel were actually true positive samples that were
missed by the expert laboratories due to a difference in DNA extraction protocols. By includ-
ing a panel of DNA samples derived from parasites, this possible counterargument can there-
fore be rejected. Three FP Schistosoma test results were reported by a single laboratory and
included both stool and DNA samples (the FP reported DNA samples were a true positive N.
americanus and Strongyloides sample). These were likely due to contamination during labora-
tory manipulations or cross-reactivity with other targets.
Over half of the FN test results were reported by a single laboratory (laboratory M), which
did not report a single positive result for any of the targets in the pilot EQAS. The reasons for
this remain unclear, as we validated the stability of the panel and this laboratory confirmed the
use of positive and negative controls.
Although educational samples are more challenging to interpret, additional information on
diagnostic performance can be obtained from them. For example, the second educational
Strongyloides DNA sample (DNA2, see Table 3) which was a hundred-fold dilution of the pos-
itive Strongyloides DNA sample (DNA1, see Table 3) was validated as educational because it
tested positive in only 4 of 5 expert laboratories. Nevertheless, in the pilot study, it was tested
positive in the majority of participating laboratories with a median Cq-value of 34.6, indicating
that this was probably close to the LOD of most assays used. One of the educational
Fig 3. The variation in the reported Cq-values across the different laboratories and targets. Each dot represents the
difference in Cq-value for one sample reported by one laboratory in comparison with the median Cq-values reported
by the expert laboratories for that sample. These differences are shown on the Y-axis, with negative values meaning
lower Cq-values compared to the median Cq-values reported across the experts, and positive values meaning higher
Cq-values. The laboratories, represented by letters, are shown on the X-axis. The number of false-negative and false-
positive results reported by each laboratory are shown by means of red stars and blue triangles, respectively.
Laboratory M was omitted from this analysis because no positive results were reported by this laboratory.
https://doi.org/10.1371/journal.pntd.0008231.g003
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Strongyloides stool samples tested positive by the majority of laboratories as well. The inclusion
of more of these challenging samples and more participating laboratories in future HEMQAS
will reveal further details about the association between used test protocols and test outcome.
The lack of information on both the absolute quantity of targets in the
HEMQAS panel and LOD of NAATs leads to ambiguous interpretations
Besides above-mentioned FP and FN test results, FN test results were reported for Schistosoma
(n = 1), Ascaris (n = 2) and N. americanus (n = 3). It remains for the laboratories to interpret
these results, but this currently remains a challenge. These FNs might be explained by less effi-
cient DNA extraction procedures and/or a poorly performing NAAT. Knowledge of both the
absolute target concentrations in the panel and of the LOD of the NAAT would allow for better
interpretation of such cases, as well as the interpretation of the educational samples. In other
words, it would allow to decide that a FN is missed because of the LOD of a NAAT or because
of another error. However, this strategy is currently complicated by the absence of a unit that
expresses qPCR results as absolute DNA concentration of the targets and that allows these
absolute concentrations to be compared if results are obtained from different assays/laborato-
ries [16,17]. Such a unit is required to compare LODs and quantitative HEMQAS values
among laboratories [17].
The high diversity in DNA extraction and NAAT protocols calls for
standardization
The current study highlights the diversity of both DNA extraction and the NAAT protocols
used for the detection and quantification of helminths in stool. Due to the design of the pilot
study we did not explore differences in protocols that may explain the variation in diagnostic
performance across laboratories. For this, a larger number of participating laboratories and
samples will be needed to address these issues. In addition, given the plethora of protocols,
more standardization in both DNA extraction and NAAT protocols should be encouraged.
However, it is unlikely that laboratories will completely relinquish their in-house protocols,
which required important investments to develop. A level of standardization that is feasible
and increases overall diagnostic performance will include (i) methodological steps that have
been proven to improve the performance of NAATs, e.g. by improving DNA extraction effi-
ciency through mechanical lysis of samples (bead beating) [25,26], (ii) the use of positive, nega-
tive and inhibition controls, (iii) regular participation in an EQAS, (iv) assessment of the LOD
of the NAATs and (v) reporting the quantity of DNA in absolute units.
Challenges for the use of NAAT in a programmatic setting
In clinical laboratories, qualitative NAAT test results for helminth infections, which indicate
presence or absence of infection in an individual patient, are sufficient to make decisions on
the initiation or success of therapy. However, there are still important obstacles that impede
implementation of NAATs in large-scale deworming programs [16,17]. In these programs,
both prevalence and intensity of infections at the population level are important indicators
that guide decision making [27]. This information is currently provided by assessing the fecal
egg counts by means of microscopic methods, of which the Kato-Katz is the most widely used.
The intensity of infection is often further classified as low, moderate or heavy [28]. NAATs
have been considered and suggested as potential alternatives to these microscopic tools, due to
their ability to detect very low levels of egg excretion [17]. However, the public health commu-
nity is currently not ready to use NAATs in control programs. The obstacles that are currently
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hampering the use of qPCR are low throughput, high cost, lack of standardization and the
absence of a quality assurance scheme. Furthermore, qPCR outcomes will need to be readily
translated to program decision algorithms.
Limitations and recommendations for future HEMQAS
Although they also cause significant health burdens in some areas, we did not include targets
such as Ancylostoma (including A. duodenale and the zoonotic A. ceylanicum) and other Schis-
tosoma species such as S. haematobium and S. japonicum, although these helminths also cause
significant health burdens in some areas [2,8]. Future HEMQAS rounds should include these
species. Moreover, an important improvement would be the inclusion of Trichuris DNA in the
DNA panel to better understand the somewhat poor results in our study for this target in stool
samples. In the present study, clinical samples were obtained from a single site (Jimma, Ethio-
pia). In order to capture (possible) more diverse species and strains, samples from geographi-
cally more dispersed regions should be included in future HEMQAS. To gain more insights
into discrepancies in diagnostic performance across laboratories, it would also be informative
to ask participating laboratories to develop a standard curve on a common target DNA mate-
rial. From 2019 onwards, SKML provides a HEMQAS open to laboratories from all over the
world.
Conclusion
We showed the technical feasibility of preparing homogeneous and stable stool and DNA sam-
ples for an international EQAS for the NAAT of Schistosoma and STHs, including Strongy-
loides. We documented a clear benefit of participating in a HEMQAS, as laboratories were able
to identify weaknesses and/or to confirm the performance of their NAATs. In contrast to
other organizations providing panels for the molecular detection of pathogens in an EQAS,
which commonly distribute only purified DNA in an artificial matrix, we demonstrated the
necessity of sending both stool and DNA samples, enabling laboratories to evaluate the entire
laboratory procedure including the important DNA extraction step. Furthermore, we showed
a high technological diversity in both DNA extraction and NAATs protocols, which under-
scores the urgent need for such an EQAS. HEMQAS should be implemented as an integral
part of the overall standardization and quality management in the field of molecular detection
of helminths. There is a need for a minimal set of recommendations to improve both the diag-
nostic performance of protocols, including but not limited to the assessment of the LOD,
reporting DNA concentration in absolute and universal units, and participating in an EQAS.
Further research should aim to identify factors that explain poor performance of NAATs and
how the NAATs can best be implemented in large-scale deworming programs.
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